Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
about
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studyIncidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysisConditional Disease Development extracted from Longitudinal Health Care Cohort Data using Layered Network Construction.[Medication treatment of rheumatoid arthritis with a history of malignancy. Epidemiological data].Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.Future therapeutic targets in rheumatoid arthritis?Safety of treatment with biologics for psoriasis in daily practice: 5-year data.Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.Summary of worldwide pediatric malignancies reported after exposure to etanercept.Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancerAn evidence-based review of skin cancer rates on biologic therapies.The delivery of evidence-based preventive care for older Americans with arthritis.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesMalignancy validation in a United States registry of rheumatoid arthritis patients.The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.Breast cancer risk in rheumatoid arthritis: an update meta-analysisUpdate on the treatment of ankylosing spondylitis.Do inflammatory bowel disease therapies cause cancer?Update of the management of chronic psoriasis: new approaches and emerging treatment options.Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of RheumatologyAutoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans.Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations.Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report.Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review.Personal and family medical history correlates of rheumatoid arthritis.Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.Treating rheumatic patients with a malignancy.Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and resultsOnline training on skin cancer diagnosis in rheumatologists: results from a nationwide randomized web-based surveySwedish registers to examine drug safety and clinical issues in RA.A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugsMalignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort studyRheumatoid Arthritis as a Therapeutic Challenge in a Patient with Lynch Syndrome.Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.
P2860
Q24674942-745951A9-B61F-45A4-973B-88B6831797D4Q26799036-CBB4D365-04FD-46E4-B177-5E908075BAD6Q27314566-4A863153-4F20-4A63-9381-AF8DC944893CQ31036951-DA2A45B1-60EF-4866-B49A-A1FCF31D8CC0Q31041008-773494F8-0DD6-40B6-B00E-D4E4839B75B1Q33346685-9503F1D0-E756-49F8-886C-B2FC64ADB6F6Q33529391-3C7CDE19-CC8A-41CD-8D60-558E7625B356Q33626895-390EF771-7ECE-4DCB-9529-B2385544F67AQ33799604-168D8E6A-95BF-4000-B1F2-67AF443144F3Q33841419-56F11090-9352-4C44-8569-0626C6D2A3B7Q33854744-2C14B51C-9E00-4F4A-81D2-8B299A9073C5Q33873620-D2E52B78-26C3-42D4-9682-A7856FABB097Q33998050-82290A4E-92E8-486F-A12A-052B72886504Q34000467-24A2EE0C-ED1C-4211-9B5C-706E60BBF0BBQ34107637-1F2C57C6-8302-4164-B60F-77FC5D459EC6Q34153010-96F6208E-9798-4F7B-9662-A66B19C02422Q34216770-B740A38B-7DF8-421E-BD31-AF774A109E15Q34287960-9426E898-EA9F-40F6-BAB1-3D35F80E7E82Q34363241-ADAA44A6-8982-4B2F-9EF6-F9BA39279AD3Q34487651-76037549-D3AD-41A8-831F-21A5B75A460AQ34592673-62E56F95-9BF8-4B60-B0E0-02D49A32BFBBQ34613890-EC5B3852-0D34-4BE8-930D-9D8F25EA5E82Q34620375-FA00D9FA-0D4B-4153-B787-361C45514176Q34641300-D887843D-6DA8-4C32-AD61-E5F226F6172EQ34642920-3E084636-BF97-4219-B26C-E6A2D5BD80FBQ35026464-00A5DBDC-1F72-493A-9962-E0D8CB4B1B1BQ35144770-D7CE002A-C44F-4821-B419-131B786393DEQ35176767-0E5C33A1-9D5D-4950-98BC-9D88408AD2B9Q35230353-B7D09E11-E12C-4895-B1DF-D3ADD2548AD2Q35554823-6D05BB0E-1FC4-4CC3-A9B3-843187E8F245Q35557863-095B7308-F00C-4E95-B153-D74070E3092AQ35605468-97D07C9A-6889-4997-AD24-201B5188A178Q35621627-FAB72D4D-B60E-4FBF-B689-07DD72948FA4Q35633961-FAF98FC3-0214-4459-B0FF-AD0087EED3A6Q35637262-F008AA6C-4293-4905-8F10-4E2455B1DE6BQ35638528-D64FC087-97E6-4D5E-91FB-2DB91686B4FAQ35813092-16C32AB0-EE67-48A9-8B26-B232AC8FCAFBQ35827560-7924D246-4A6A-4186-9418-12BD61F1286CQ35953319-00C5D6F3-FBF1-417B-8D2D-B8C5B20D6E74Q35954490-1A380453-7EAE-4404-92D2-F3A1E6F909C9
P2860
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Risks of solid cancers in pati ...... ur necrosis factor antagonists
@ast
Risks of solid cancers in pati ...... ur necrosis factor antagonists
@en
type
label
Risks of solid cancers in pati ...... ur necrosis factor antagonists
@ast
Risks of solid cancers in pati ...... ur necrosis factor antagonists
@en
prefLabel
Risks of solid cancers in pati ...... ur necrosis factor antagonists
@ast
Risks of solid cancers in pati ...... ur necrosis factor antagonists
@en
P2093
P2860
P356
P1476
Risks of solid cancers in pati ...... ur necrosis factor antagonists
@en
P2093
Baecklund E
Bertilsson L
Feltelius N
Jacobsson LT
Lindblad S
P2860
P304
P356
10.1136/ARD.2004.033993
P407
P577
2005-04-13T00:00:00Z